



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22315-1450
www.uspto.gov

APPLICATION NUMBER	FILING OR 371 (c) DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/774,721	02/09/2004	Ralf Jockers	FRA-V2003/0005USNP

05487
ROSS J. OEHLER
AVENTIS PHARMACEUTICALS INC.
ROUTE 202-206
MAIL CODE: D303A
BRIDGEWATER, NJ 08807

CONFIRMATION NO. 9535

FORMALITIES LETTER



OC000000012644021

Date Mailed: 05/13/2004

NOTICE TO FILE MISSING PARTS OF NONPROVISIONAL APPLICATION

FILED UNDER 37 CFR 1.53(b)

Filing Date Granted

Items Required To Avoid Abandonment:

An application number and filing date have been accorded to this application. The item(s) indicated below, however, are missing. Applicant is given **TWO MONTHS** from the date of this Notice within which to file all required items and pay any fees required below to avoid abandonment. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a).

- The oath or declaration is unsigned.
- To avoid abandonment, a late filing fee or oath or declaration surcharge as set forth in 37 CFR 1.16(e) of \$130 for a non-small entity, must be submitted with the missing items identified in this letter.
- The application was filed in a language other than English. Applicant is required to provide an English translation of the specification and a statement that the translation is accurate. (See 37 CFR 1.52(d)).
- Applicant must file an English translation of the application, the \$ 130 fee set forth in 37 CFR 1.17(i), unless previously submitted, and a statement that the translation is accurate (37 CFR 1.52(d)).
- Because your specification was filed in a language other than English, the Office was unable to determine the number of claims submitted. Additional claim fees may be due once the number of claims can be determined.

The application is informal since it does not comply with the regulations for the reason(s) indicated below.

The required item(s) identified below must be timely submitted to avoid abandonment:

- Replacement drawings in compliance with 37 CFR 1.84 and 37 CFR 1.121 are required. The drawings submitted are not acceptable because:
 - The drawing figures contain text that is not in English (including, for example, a flow chart that was originally not in English that has been marked up to include the English text) (see 37 CFR 1.84(p)(2) and 37 CFR 1.52(d)(1)). See Figure(s) 1-13.

08/17/2004 YPOLITE1 00000046 181982 10774721

01 FC:1051 130.00 DA

08/18/2004 YPOLITE1 00000038 181982 10774721

01 FC:1053 130.00 DA

- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

SUMMARY OF FEES DUE:

Total additional fee(s) required for this application is **\$260** for a Large Entity

- **\$130** Late oath or declaration Surcharge.
- **\$130** for English translation surcharge required.

Replies should be mailed to: Mail Stop Missing Parts
Commissioner for Patents
P.O. Box 1450
Alexandria VA 22313-1450


*A copy of this notice **MUST** be returned with the reply.*



Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventive Application of
Jockers et al.

Examiner: N/A

Art Unit: N/A

Application No.: 10/774,721

Filed: February 9, 2004

Title: **Oligonucleotides Which Inhibit Expression
Of the OB-RGRP Protein And Method For
Detecting Compounds Which Modify The
Interaction Between Proteins Of the OB-
RGRP Family and The Leptin Receptor**

I hereby certify that this correspondence is being
deposited with the United States Postal Service as First
Class Mail in an envelope addressed to Mail Stop
Missing Parts, Commissioner for Patents, P.O. Box
1450, Alexandria, VA 22313-1450, on

Aug. 12, 2004
Date of Deposit

[Signature]
Signature

**COMPLETION OF FILING REQUIREMENTS -
NONPROVISIONAL APPLICATION**

Mail Stop Missing Parts
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

This replies to the Notice of Filing Missing Parts of Application (PTO-1533) mailed May 13, 2004.
A copy of the Notice to File Missing Parts of Application - Filing Date Granted (Form PTO-1533) is
enclosed.

Submitted herewith is an English translation of the non-English language application papers as
originally filed. Also submitted herewith is a statement by the translator of the accuracy of the
translation. It is requested that this translation be used as the copy for examination purposes.

Please charge the \$130.00 fee involved to Deposit Account No. 18-1982. The Commissioner is
hereby authorized to charge any additional fees which may be required by this paper, or credit any
overpayment, to Account No. 18-1982. Two duplicate copies of this sheet are enclosed.

Respectfully submitted,

[Signature]

F. Aaron Dubberley, Reg. No. 41,001
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, New Jersey 08807-0800
Telephone: 908-231-3737
Telefax: 908-231-2626

Aventis Docket No. FRAV2003/0005USNP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
Jockers et al.

Examiner: N/A

Art Unit: N/A

Application No.: 10/774,721

Filed: February 9, 2004

Title: **Oligonucleotides Which Inhibit Expression
Of the OB-RGRP Protein And Method For
Detecting Compounds Which Modify The
Interaction Between Proteins Of the OB-
RGRP Family and The Leptin Receptor**

I hereby certify that this correspondence is being
deposited with the United States Postal Service as First
Class Mail in an envelope addressed to Mail Stop
Missing Parts, Commissioner for Patents, P.O. Box
1450, Alexandria, VA 22313-1450, on

Aug 12, 2004
Date of deposit

[Signature]
Signature

REPLY TO NOTICE OF MISSING PARTS
UNDER 37 C.F.R. 1.53(f)

Mail Stop Missing Parts
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

In response to the "NOTICE TO FILE MISSING PARTS OF APPLICATION - FILING DATE
GRANTED" which was mailed on May 13, 2004 and which indicated that the oath or declaration was
missing, Applicants submit herewith the Declaration for the present application and a copy of Form PTO-
1533.

Also enclosed are a verified English translation of the specification and drawings, a printout of the
Sequence Listing, a diskette containing a computer readable copy required by 37 C.F.R. 1.821 and a
Statement Regarding Content Of Paper And Computer Readable Copies Pursuant To 37 C.F.R. 1.821 (f).

Since the enclosed verified English Translation includes drawings labeled properly in English, further
revised drawings (as requested in the Notice of Missing Parts) are not necessary.

Finally, a Petition For A One Month Extension of Time is enclosed.

Please charge the \$130.00 fee involved to Deposit Account No. 18-1982. The Commissioner is
hereby authorized to charge any additional fees which may be required by this paper, or credit any
overpayment to Account No. 18-1982. Two duplicate copies of this sheet are enclosed.

Respectfully submitted,

[Signature]

F. Aaron Dubberley, Reg. No. 41,001
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-3737
Telefax (908) 231-2626
Docket No. FRAV2003/0005USNP